Zymeworks, a Vancouver, Canada-headquartered clinical-stage biopharmaceutical company, has opened a new 10,000-square-foot laboratory facility in Vancouver, Canada, for developing antibody drug conjugates (ADCs).

The new lab will provide the company with increased control over discovery research, antibody generation, medicinal chemistry, and bioconjugation for generating ADCs as well as for developing multi-functional proteins.

Source: Zymeworks